News

Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients, announced that the…
Read More...

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) approved expanded use of ORKAMBI (lumacaftor/ivacaftor) to include children with cystic…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with…
Read More...

Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, announces that the US Food and…
Read More...

Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...

Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...

Cambrex announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point,…
Read More...

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…
Read More...

Novavax, Inc. announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a…
Read More...

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per…
Read More...

Amneal Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of…
Read More...

Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions ("IPS"), a division of Interpace…
Read More...

Guardant Health, Inc. announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A,…
Read More...

OKYO Pharma Limited a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022 IND…
Read More...

Novartis announced that the European Commission (EC) has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia…
Read More...

GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. The companies plan to advance the development of…
Read More...

The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize…
Read More...

Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)…
Read More...

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment…
Read More...